Lone Star Bio Ventures

Lone Star Bio Ventures

Lone Star Bio Ventures was established to capture early-stage life science opportunities within the Texas innovation corridor, a region dense with academic medical research and relatively underserved by coastal seed funds. The firm focuses on pre-institutional rounds. It backs companies developing novel biologics, diagnostic platforms, and care-delivery technologies before large-scale clinical trials begin. The strategy spans therapeutics, medical devices, and digital health. Seed allocations target rare-disease drug platforms spun out of UT Southwestern and portable diagnostic tools matched to the needs of the state's rural hospital networks. The firm structures investments as equity rounds with participation in follow-on bridge notes, working alongside angel syndicates and regional venture philanthropies to position companies for larger DFW-based growth funds. The geographic footprint concentrates on Texas, with selective exposure to Oklahoma and Louisiana life-science accelerators. Team size and total deployment are not publicly disclosed. The firm operates from a single office in Richardson, part of the Telecom Corridor that has attracted a cluster of health-IT service providers and middle-market medtech acquirers. There are no known parallel funds, philanthropic foundations, or club-commitment structures under the Lone Star Bio umbrella. The firm's most recent verifiable posture remains its foundational seed-stage orientation toward Texas-bred biomedical intellectual property. A key structural differentiator is Lone Star's regional lock on de novo life-science company formation in North Texas. While biotech venture capital concentrates in Boston and the Bay Area, the firm sits inside one of the largest academic-medical-to-provider ecosystems in the United States, with a mandate scaled to the check sizes that local founders actually require to reach proof-of-concept. This regional monopoly on early-stage deal access in a top-5 US metro makes it a specialized point of entry for co-investors seeking Texas-originated health sciences exposure.